Autoantibodies in inflammatory arthritis

Autoimmunity Reviews

Volumn 15, Issue 7, 2016, Pages 673-683

  Conigliaro, P ^a,b   Chimenti, M S ^a,b   Triggianese, P ^a,b   Sunzini, F ^a,b   Novelli, L ^a,b   Perricone, C ^a,b   Perricone, R ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA ANTIBODY; RHEUMATOID FACTOR; SILICON DIOXIDE; TOBACCO SMOKE;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; AUTOIMMUNITY; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; PROGNOSIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SENSIBILITY; TREATMENT RESPONSE; ANIMAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BLOOD; EARLY DIAGNOSIS; IMMUNOLOGY;

ANIMALS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; BIOMARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PROGNOSIS;

EID: 84961960751     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.03.003     Document Type: Review

References (189)

1. Sakkas L.I., Bogdanos D.P., Katsiari C., Platsoucas C.D. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. Autoimmun Rev 2014, 13(11):1114-1120.
2. Valesini G., Gerardi M.C., Iannuccelli C., Pacucci V.A., Pendolino M., Shoenfeld Y. Citrullination and autoimmunity. Autoimmun Rev 2015, 14(6):490-497.
3. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7(6):429-442.
4. Gianchecchi E., Fierabracci A. Gene/environment interactions in the pathogenesis of autoimmunity: new insights on the role of toll-like receptors. Autoimmun Rev 2015, 14(11):971-983.
5. Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30(11):1205-1213.
6. Huizinga T.W., Amos C.I., van der Helm-van Mil A.H., Chen W., van Gaalen F.A., Jawaheer D., et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005, 52(11):3433-3438.
7. Klareskog L., Rönnelid J., Lundberg K., Padyukov L., Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008, 26:651-675.
8. Auger I., Roudier C., Guis S., Balandraud N., Roudier J. HLA-DRB1*0404 is strongly associated with anticalpastatin antibodies in rheumatoid arthritis. Ann Rheum Dis 2007, 66(12):1588-1593.
9. James E.A., Moustakas A.K., Bui J., Papadopoulos G.K., Bondinas G., Buckner J.H., et al. HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum 2010, 62(10):2909-2918.
10. Bax M., van Heemst J., Huizinga T.W., Toes R.E. Genetics of rheumatoid arthritis: what have we learned?. Immunogenetics 2011, 63(8):459-466.
11. Hill J.A., Southwood S., Sette A., Jevnikar A.M., Bell D.A., Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003, 171(2):538-541.
12. Ceccarelli F., D'Alfonso S., Perricone C., Carlomagno Y., Alessandri C., Croia C., et al. The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012, 30(6):939-942.
13. Ling S., Li Z., Borschukova O., Xiao L., Pumpens P., Holoshitz J. The rheumatoid arthritis shared epitope increases cellular susceptibility to oxidative stress by antagonizing an adenosine-mediated anti-oxidative pathway. Arthritis Res Ther 2007, 9(1):R5.
14. Ling S., Pi X., Holoshitz J. The rheumatoid arthritis shared epitope triggers innate immune signaling via cell surface calreticulin. J Immunol 2007, 179(9):6359-6367.
15. De Almeida D.E., Ling S., Pi X., Hartmann-Scruggs A.M., Pumpens P., Holoshitz J. Immune dysregulation by the rheumatoid arthritis shared epitope. J Immunol 2010, 185(3):1927-1934.
16. Holoshitz J., Liu Y., Fu J., Joseph J., Ling S., Colletta A., et al. An HLA-DRB1-coded signal transduction ligand facilitates inflammatory arthritis: a new mechanism of autoimmunity. J Immunol 2013, 190(1):48-57.
17. van Heemst J., Hensvold A.H., Jiang X., van Steenbergen H., Klareskog L., Huizinga T.W., et al. Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA. Ann Rheum Dis 2015, [pii: annrheumdis-2015-207802].
18. Perricone C., Ceccarelli F., Valesini G. An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun Rev 2011, 10(10):599-608.
19. Gregersen P.K. Gaining insight into PTPN22 and autoimmunity. Nat Genet 2005, 37(12):1300-1302.
20. Stanford S.M., Bottini N. PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 2014, 10(10):602-611.
21. Carlton V.E., Hu X., Chokkalingam A.P., Schrodi S.J., Brandon R., Alexander H.C., et al. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am J Hum Genet 2005, 77(4):567-581.
22. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75(2):330-337.
23. Ikari K., Kuwahara M., Nakamura T., Momohara S., Hara M., Yamanaka H., et al. Association between PADI4 and rheumatoid arthritis: a replication study. Arthritis Rheum 2005, 52(10):3054-3057.
24. Kang C.P., Lee H.S., Ju H., Cho H., Kang C., Bae S.C. A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum 2006, 54(1):90-96.
25. Hou S., Gao G.P., Zhang X.J., Sun L., Peng W.J., Wang H.F., et al. PADI4 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Mod Rheumatol 2013, 23(1):50-60.
26. Terao C., Ohmura K., Kochi Y., Ikari K., Okada Y., Shimizu M., et al. Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. Arthritis Res Ther Apr 18 2015, 17:104.
27. Bossini-Castillo L., de Kovel C., Kallberg H., van 't Slot R., Italiaander A., Coenen M., et al. A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. Ann Rheum Dis Mar 2015, 74(3):e15.
28. Alessandri C., Conti F., Conigliaro P., Mancini R., Massaro L., Valesini G. Seronegative autoimmune diseases. Ann N Y Acad Sci 2009, 1173:52-59.
29. Irigoyen P., Lee A.T., Wener M.H., Li W., Kern M., Batliwalla F., et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum Dec 2005, 52(12):3813-3818.
30. Verpoort K.N., van Gaalen F.A., van der Helm-van Mil A.H., Schreuder G.M., Breedveld F.C., Huizinga T.W., et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum Oct 2005, 52(10):3058-3062.
31. Lundström E., Källberg H., Smolnikova M., Ding B., Rönnelid J., Alfredsson L., et al. Opposing effects of HLA-DRB1*13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009, 60(4):924-930.
32. Sigurdsson S., Padyukov L., Kurreeman F.A., Liljedahl U., Wiman A.C., Alfredsson L., et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007, 56(7):2202-2210.
33. Wang C.J., Yang Y.J., Huang C.C. The effects of shockwave on systemic concentrations of nitric oxide level, angiogenesis and osteogenesis factors in hip necrosis. Rheumatol Int 2011, 31(7):871-877.
34. Garnier S., Dieudé P., Michou L., Barbet S., Tan A., Lasbleiz S., et al. IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis. Ann Rheum Dis 2007, 66(6):828-831.
35. Rueda B., Reddy M.V., González-Gay M.A., Balsa A., Pascual-Salcedo D., Petersson I.F., et al. Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis. Arthritis Rheum 2006, 54(12):3815-3819.
36. Gutierrez-Achury J., Zorro M.M., Ricaño-Ponce I., Zhernakova D.V., Coeliac Disease Immunochip Consortium, RACI Consortium, et al. Functional implications of disease-specific variants in loci jointly associated with coeliac disease and rheumatoid arthritis. Hum Mol Genet Jan 1 2016, 25(1):180-190.
37. Perricone C., Versini M., Ben-Ami D., Gertel S., Watad A., Segel M.J., et al. Smoke and autoimmunity: the fire behind the disease. Autoimmun Rev Apr 2016, 15(4):354-374.
38. Perricone R., de Carolis C., de Sanctis G., Fontana L. Complement activation by cigarette smoke condensate and tobacco infusion. Arch Environ Health 1983, 38(3):176-179.
39. Kobayashi S., Okamoto H., Iwamoto T., Toyama Y., Tomatsu T., Yamanaka H., et al. A role for the aryl hydrocarbon receptor and the dioxin TCDD in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47(9):1317-1322.
40. Henley D.V., Bellone C.J., Williams D.A., Ruh T.S., Ruh M.F. Aryl hydrocarbon receptor-mediated posttranscriptional regulation of IL-1beta. Arch Biochem Biophys 2004, 422(1):42-51.
41. Ospelt C., Camici G.G., Engler A., Kolling C., Vogetseder A., Gay R.E., et al. Smoking induces transcription of the heat shock protein system in the joints. Ann Rheum Dis 2014 Jul, 73(7):1423-1426.
42. Pedersen M., Jacobsen S., Klarlund M., Pedersen B.V., Wiik A., Wohlfahrt J., et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006, 8(4):R133.
43. Klareskog L., Stolt P., Lundberg K., Källberg H., Bengtsson C., Grunewald J., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54(1):38-46.
44. Shi J., van Veelen P.A., Mahler M., Janssen G.M., Drijfhout J.W., Huizinga T.W., et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 2014, 13(3):225-230.
45. Jaisson S., Larreta-Garde V., Bellon G., Hornebeck W., Garnotel R., Gillery P. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol 2007, 26(3):190-196. [Epub 2006 Nov 10].
46. Springer G.F., Yang H.J., Desai P.R., Jirgensons B. Effect of carbamylation of lysine epsilon-amino groups on the activity of blood group specific glycoproteins. Immunol Commun 1975, 4(6):553-564.
47. Sirpal S. Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. Clin Sci (Lond) 2009, 116(9):681-695.
48. Schreier S.M., Hollaus M., Hermann M., Jirovetz L., Exner M., Kapiotis S., et al. Carbamoylated free amino acids in uremia: HOCl generates volatile protein modifying and cytotoxic oxidant species from N-carbamoyl-threonine but not threonine. Biochimie 2012, 94(11):2441-2447.
49. Shi J., van de Stadt L.A., Levarht E.W., Huizinga T.W., Hamann D., van Schaardenburg D., et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 2014, 73(4):780-783.
50. Jiang X., Källberg H., Chen Z., Ärlestig L., Rantapää-Dahlqvist S., Davila S., et al. An immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) 2016, 55(1):149-155.
51. Seror R., Le Gall-David S., Bonnaure-Mallet M., Schaeverbeke T., Cantagrel A., Minet J., et al. Association of anti-Porphyromonas gingivalis antibody titers with nonsmoking status in early rheumatoid arthritis: results from the prospective French cohort of patients with early rheumatoid arthritis. Arthritis Rheumatol. 2015, 67(7):1729-1737.
52. Mikuls T.R., Payne J.B., Yu F., Thiele G.M., Reynolds R.J., Cannon G.W., et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014, 66(5):1090-1100.
53. de Pablo P., Dietrich T., McAlindon T.E. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol 2008, 35(1):70-76.
54. Wegner N., Wait R., Sroka A., Eick S., Nguyen K.A., Lundberg K., et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010, 62(9):2662-2672.
55. Kharlamova N., Jiang X., Sherina N., Potempa B., Israelsson L., Quirke A.M., et al. Antibodies to Porphyromonas gingivalis indicate interaction between oral infection, smoking and risk genes in rheumatoid arthritis etiology. Arthritis Rheumatol 2016, 68(3):604-613.
56. Yahya A., Bengtsson C., Larsson P., Too C.L., Mustafa A.N., Abdullah N.A., et al. Silica exposure is associated with an increased risk of developing ACPA-positive rheumatoid arthritis in an Asian population: evidence from the Malaysian MyEIRA case-control study. Mod Rheumatol 2014, 24(2):271-274.
57. Otsuki T., Hayashi H., Nishimura Y., Hyodo F., Maeda M., Kumagai N., et al. Dysregulation of autoimmunity caused by silica exposure and alteration of Fas-mediated apoptosis in T lymphocytes derived from silicosis patients. Int J Immunopathol Pharmacol 2011, 24(1 Suppl):11S-16S.
58. Rantapää-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48(10):2741-2749.
59. Aho K., Palosuo T., Raunio V., Puska P., Aromaa A., Salonen J.T. When does rheumatoid disease start?. Arthritis Rheum 1985, 28(5):485-489.
60. Majka D.S., Deane K.D., Parrish L.A., Lazar A.A., Barón A.E., Walker C.W., et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008, 67(6):801-807.
61. Kokkonen H., Mullazehi M., Berglin E., Hallmans G., Wadell G., Rönnelid J., et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011, 13(1):R13.
62. Nielen M.M., van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50(2):380-386.
63. Brink M., Hansson M., Mathsson L., Jakobsson P.J., Holmdahl R., Hallmans G., et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013, 65(4):899-910.
64. Willemze A., Böhringer S., Knevel R., Levarht E.W., Stoeken-Rijsbergen G., Houwing-Duistermaat J.J., et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 2012, 71(2):268-274.
65. van der Woude D., Rantapää-Dahlqvist S., Ioan-Facsinay A., Onnekink C., Schwarte C.M., Verpoort K.N., et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010, 69(8):1554-1561.
66. Stoop J.N., Liu B.S., Shi J., Jansen D.T., Hegen M., Huizinga T.W., et al. Antibodies specific for carbamylated proteins precede the onset of clinical symptoms in mice with Collagen induced arthritis. PLoS One 2014, 9(7).
67. Conigliaro P., Benson R.A., Patakas A., Kelly S.M., Valesini G., Holmdahl R., et al. Characterization of the anticollagen antibody response in a new model of chronic polyarthritis. Arthritis Rheum 2011, 63(8):2299-2308.
68. Krabben A., Huizinga T.W., van der Helm-van Mil A.H. Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis. Ann Rheum Dis 2012, 71(2):238-241.
69. van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., de Jong B.A., Breedveld F.C., Verweij C.L., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004, 50(3):709-715.
70. van Venrooij W.J., van Beers J.J., Pruijn G.J. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011, 7(7):391-398.
71. van Venrooij W.J., Zendman A.J., Pruijn G.J. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006, 6(1):37-41.
72. Bos W.H., Wolbink G.J., Boers M., Tijhuis G.J., de Vries N., van der Horst-Bruinsma I.E., et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010, 69(3):490-494.
73. van de Stadt L.A., van der Horst A.R., de Koning M.H., Bos W.H., Wolbink G.J., van de Stadt R.J., et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011, 70(1):128-133.
74. Nam J.L., Hunt L., Hensor E.M., Emery P. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study. Ann Rheum Dis 2015, [pii: annrheumdis-2015-207871].
75. Shi J., van de Stadt L.A., Levarht E.W., Huizinga T.W., Toes R.E., Trouw L.A., et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013, 65(4):911-915.
76. Brink M., Verheul M.K., Rönnelid J., Berglin E., Holmdahl R., Toes R.E., et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther 2015, 17:25.
77. Mjaavatten M.D., van der Heijde D., Uhlig T., Haugen A.J., Nygaard H., Sidenvall G., et al. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis. Arthritis Res Ther 2010, 12(3):R76.
78. Shi J., van Steenbergen H.W., van Nies J.A., Levarht E.W., Huizinga T.W., van der Helm-van Mil A.H., et al. The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Res Ther 2015, 17:339.
79. Muller P.C., Anink J., Shi J., Levarht E.W., Reinards T.H., Otten M.H., et al. Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. Ann Rheum Dis 2013, 72(12):2053-2055.
80. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O.I.I.I., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69(9):1580-1588.
81. Sutton B., Corper A., Bonagura V., Taussig M. The structure and origin of rheumatoid factors. Immunol Today 2000, 21(4):177-183.
82. Bugatti S., Codullo V., Caporali R., Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 2007, 7(2):137-142.
83. van der Helm-van Mil A.H., Verpoort K.N., Breedveld F.C., Toes R.E., Huizinga T.W. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7(5):R949-R958.
84. van der Woude D., Young A., Jayakumar K., Mertens B.J., Toes R.E., van der Heijde D., et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009, 60(8):2262-2271.
85. Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101(1):273-281.
86. Vossenaar E.R., Radstake T.R., van der Heijden A., van Mansum M.A., Dieteren C., de Rooij D.J., et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004, 63(4):373-381.
87. Masson-Bessière C., Sebbag M., Durieux J.J., Nogueira L., Vincent C., Girbal-Neuhauser E., et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000, 119(3):544-552.
88. Reparon-Schuijt C.C., van Esch W.J., van Kooten C., Schellekens G.A., de Jong B.A., van Venrooij W.J., et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001, 44(1):41-47.
89. Schellekens G.A., Visser H., de Jong B.A., van den Hoogen F.H., Hazes J.M., Breedveld F.C., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43(1):155-163.
90. Levesque M.C., Zhou Z., Moreland L.W. Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum 2009, 60(8):2211-2215.
91. Trouw L.A., Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012, 12(2):318-322.
92. van Beers J.J., Willemze A., Jansen J.J., Engbers G.H., Salden M., Raats J., et al. ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res Ther 2013, 15(5):R140.
93. Verheul M.K., Fearon U., Trouw L.A., Veale D.J. Biomarkers for rheumatoid and psoriatic arthritis. Clin Immunol 2015, 161(1):2-10.
94. Hassfeld W., Steiner G., Studnicka-Benke A., Skriner K., Graninger W., Fischer I., et al. Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum 1995, 38(6):777-785.
95. Hassfeld W., Steiner G., Hartmuth K., Kolarz G., Scherak O., Graninger W., et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 1989, 32(12):1515-1520.
96. Nell V.P., Machold K.P., Stamm T.A., Eberl G., Heinzl H., Uffmann M., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005, 64(12):1731-1736.
97. Konig M.F., Giles J.T., Nigrovic P.A., Andrade F. Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. Ann Rheum Dis 2016, [pii: annrheumdis-2015-208529].
98. Bang H., Egerer K., Gauliard A., Lüthke K., Rudolph P.E., Fredenhagen G., et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007, 56(8):2503-2511.
99. Rojanasantikul P., Pattrapornpisut P., Anuruckparadorn K., Katchamart W. The performance of a point of care test for detection of anti-mutated citrullinated vimentin and rheumatoid factor in early rheumatoid arthritis. Clin Rheumatol 2014, 33(7):919-923.
100. Lee Y.H., Bae S.C., Song G.G. Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: a meta-analysis. Z Rheumatol 2015, 74(10):911-918.
101. Degboé Y., Constantin A., Nigon D., Tobon G., Cornillet M., Schaeverbeke T., et al. Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort. RMD Open 2015, 1(1).
102. Svärd A., Kastbom A., Söderlin M.K., Reckner-Olsson Å., Skogh T. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J Rheumatol 2011, 38(7):1265-1272.
103. Cvetkovic J.T., Wållberg-Jonsson S., Ahmed E., Rantapää-Dahlqvist S., Lefvert A.K. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002, 41(9):988-995.
104. Thiele G.M., Duryee M.J., Anderson D.R., Klassen L.W., Mohring S.M., Young K.A., et al. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol. 2015, 67(3):645-655.
105. Vehkala L., Ukkola O., Kesäniemi Y.A., Kähönen M., Nieminen M.S., Salomaa V., et al. Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetes. Ann Med 2013, 45(8):501-510.
106. Rolla R., Vay D., Mottaran E., Parodi M., Traverso N., Aricó S., et al. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology 2000, 31(4):878-884.
107. Zhao J., Zhao Y., He J., Jia R., Li Z. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol 2008, 35(6):969-974.
108. Halvorsen E.H., Pollmann S., Gilboe I.M., van der Heijde D., Landewé R., Ødegård S., et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis 2008, 67(3):414-417.
109. Auger I., Balandraud N., Rak J., Lambert N., Martin M., Roudier J. New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 2009, 68(4):591-594.
110. Darrah E., Giles J.T., Ols M.L., Bull H.G., Andrade F., Rosen A. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med 2013, 5(186). [186ra65].
111. Li W., Wang W., Sun S., Sun Y., Pan Y., Wang L., et al. Autoantibodies against the catalytic domain of BRAF are not specific serum markers for rheumatoid arthritis. PLoS One 2011, 6(12).
112. Burkhardt H., Koller T., Engström A., Nandakumar K.S., Turnay J., Kraetsch H.G., et al. Epitope-specific recognition of type II Collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum Sep 2002, 46(9):2339-2348.
113. Rowley M.J1., Williamson D.J., Mackay I.R. Evidence for local synthesis of antibodies to denatured collagen in the synovium in rheumatoid arthritis. Arthritis Rheum Dec 1987, 30(12):1420-1425.
114. Tarkowski A1., Klareskog L., Carlsten H., Herberts P., Koopman W.J. Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum Sep 1989, 32(9):1087-1092.
115. Kim W.U1., Yoo W.H., Park W., Kang Y.M., Kim S.I., Park J.H., et al. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol Mar 2000, 27(3):575-581.
116. Mullazehi M1., Mathsson L., Lampa J., Rönnelid J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis Apr 2007, 66(4):537-541.
117. Bläss S1., Union A., Raymackers J., Schumann F., Ungethüm U., Müller-Steinbach S., et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum Apr 2001, 44(4):761-771.
118. Shoda H., Fujio K., Shibuya M., Okamura T., Sumitomo S., Okamoto A., et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 2011, 13(6):R191.
119. Bodman-Smith M.D., Corrigall V.M., Berglin E., Cornell H.R., Tzioufas A.G., Mavragani C.P., et al. Antibody response to the human stress protein BiP in rheumatoid arthritis. Rheumatology (Oxford) Oct 2004, 43(10):1283-1287.
120. Shoda H., Fujio K., Sakurai K., Ishigaki K., Nagafuchi Y., Shibuya M., et al. Proc Natl Acad Sci U S A. 2011 Autoantigen BiP-derived HLA-DR4 epitopes differentially recognized by effector and regulatory T Cells in rheumatoid arthritis. Arthritis Rheumatol May 2015, 67(5):1171-1181.
121. Jiang X., Trouw L.A., van Wesemael T.J., Shi J., Bengtsson C., Källberg H., et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis Oct 2014, 73(10):1761-1768.
122. Shi J., Knevel R., Suwannalai P., van der Linden M.P., Janssen G.M., van Veelen P.A., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A Oct 18 2011, 108(42):17372-17377.
123. Gan R.W., Trouw L.A., Shi J., Toes R.E., Huizinga T.W., Demoruelle M.K., et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J Rheumatol Apr 2015, 42(4):572-579.
124. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423(6937):356-361.
125. Besada E., Nikolaissen C., Nossent H. Should rheumatoid factor in rheumatoid arthritis be sent to Davy Jones's Locker?. Scand J Rheumatol 2012, 41(2):85-88.
126. Forslind K., Ahlmen M., Eberhardt K., Hafstrom I., Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004, 63(9):1090-1095.
127. Quinn M.A., Gough A.K., Green M.J., et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006, 45:478-480.
128. De R.L. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004, 63:1587-1593.
129. Shidara K., Inoue E., Hoshi D., et al. Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int 2012, 32:361-366.
130. Humphreys J.H., van Nies J., Chipping J., et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 2014, 16:483.
131. López-Longo F.J1., Sánchez-Ramón S., Carreño L. The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?. Drug News Perspect Nov 2009, 22(9):543-548.
132. Willemze A., Trouw L.A., Toes R.E., Huizinga T.W. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol Jan 31 2012, 8(3):144-152.
133. Nielen M.M., van der Horst A.R., van Schaardenburg D., van der Horst-Bruinsma I.E., van de Stadt R.J., Aarden L., et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis Aug 2005, 64(8):1199-1204.
134. Chen D., Li H., Liang L., Xiao Y., Xu T., Qiu Q., et al. Clinical features and independent predictors in the further development of rheumatoid arthritis in undifferentiated arthritis. Rheumatol Int Nov 2013, 33(11):2827-2832.
135. Bizzaro N., Bartoloni E., Morozzi G., Manganelli S., Riccieri V., Sabatini P., et al. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther Jan 22 2013, 15(1):R16.
136. Humphreys J.H., Verheul M.K., Barton A., MacGregor A.J., Lunt M., Toes R.E., et al. Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis Oct 6 2015.
137. Alessandri C., Bartosiewicz I., Pendolino M., Mancini R., Colasanti T., Pecani A., et al. Anti-carbamylated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients: lack of correlation with anti-cyclic citrullinated protein antibodies and rheumatoid factor. Clin Exp Rheumatol 2015, 33(6):824-830.
138. Bartoloni E., Alunno A., Bistoni O., Bizzaro N., Migliorini P., Morozzi G., et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 2012, 11(11).
139. Mansour Howaida E., Metwaly Khaled M., Hassan Iman A., Elshamy Hebat-Allah A., Elbeblawy Moataz M.S. Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection. Clin Med Insights Arthritis Musculoskelet Disord 2010, 3:33-42.
140. Mullazehi M., Wick M.C., Klareskog L., van Vollenhoven R., Rönnelid J. Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. Arthritis Res Ther 2012, 14(3):R100.
141. Sihvonen S., Korpela M., Laippala P., Mustonen J., Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004, 33(4):221-227.
142. Turesson C., Eberhardt K., Jacobsson L.T., Lindqvist E. Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort. Ann Rheum Dis 2007, 66(11):1543-1544.
143. López-Longo F.J., Oliver-Miñarro D., de la Torre I., González-Díaz De Rábago E., Sánchez-Ramón S., Rodríguez-Mahou M., et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61(4):419-424.
144. Visser K., Verpoort K.N., van Dongen H., van der Kooij S.M., Allaart C.F., Toes R.E., et al. Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 2008, 67(8):1194-1195.
145. van Dongen H., van Aken J., Lard L.R., Visser K., Ronday H.K., Hulsmans H.M., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 56(5):1424-1432.
146. de Vries-Bouwstra J.K1., Goekoop-Ruiterman Y.P., Verpoort K.N., Schreuder G.M., Ewals J.A., Terwiel J.P., et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008, 58(5):1293-1298.
147. Sokolove J., Schiff M., Fleischmann R., Weinblatt M.E., Connolly S.E., Johnsen A., et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 2016 Apr, 75(4):709-714.
148. Gardette A., Ottaviani S., Tubach F., Roy C., Nicaise-Roland P., Palazzo E., et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine 2014, 81(5):416-420.
149. Moll J.M., Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3(1):55-78.
150. Chimenti M.S., Triggianese P., Nuccetelli M., Terracciano C., Crisanti A., Guarino M.D., et al. Auto-reactions, autoimmunity and psoriatic arthritis. Autoimmun Rev 2015, 14(12):1142-1146.
151. Stolwijk C., van Onna M., Boonen A., van Tubergen A. The global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken) 29 2015, 10.1002/acr.22831.
152. Acosta Felquer M.L., FitzGerald O. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol 2015, 33(5 Suppl 93):S26-S30.
153. Haroon M., FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol 2016, 28:1-12.
154. Esposito M., Giunta A., Mazzotta A., Zangrilli A., Babino G., Bavetta M., et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 2012, 225(4):312-319.
155. Versini M., Jeandel P.Y., Rosenthal E., Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014, 13(9):981-1000.
156. Haque N., Lories R.J., de Vlam K. Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol 2016, 43(2):376-382.
157. Coates L.C., Kavanaugh A., Mease P.J., Soriano E.R., Laura Acosta Felquer M., et al. Group for research and assessment of psoriasis and psoriatic arthritis: treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2015, (2016 Jan 8).
158. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54(8):2665-2673.
159. Congi L., Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol 2010, 28(3):304-310.
160. Teoli M., Zangrilli A., Chimenti M.S., Talamonti M., Bavetta M., Graceffa D., et al. Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. Clin Dev Immunol 2012, 2012:823854.
161. Kane D., Stafford L., Bresnihan B., FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003, 42:1460-1468.
162. Chimenti M.S., Ballanti E., Perricone C., Cipriani P., Giacomelli R., Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 2013, 12:599-606.
163. FitzGerald O., Haroon M., JT Giles, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther 2015, 17:115.
164. Cañete J.D., Santiago B., Cantaert T., Sanmartí R., Palacin A., Celis R., et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007, 66(6):720-726.
165. Conigliaro P., Triggianese P., Perricone C., Chimenti M.S., Di Muzio G., Ballanti E., et al. Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. Clin Exp Immunol 2014, 177:234-243.
166. van Kuijk A.W., Tak P.P. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep 2011, 13(4):353-359.
167. Bandinelli F., Denaro V., Prignano F., Collaku L., Ciancio G., Matucci-Cerinic M. Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: correlation with clinical, dermatological, serological and genetic indices. Clin Exp Rheumatol 2015, 33(3):330-335.
168. Korendowych E., Owen P., Ravindran J., Carmichael C., McHugh N. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 2005, 44(8):1056-1060.
169. Pasquetti P., Morozzi G., Galeazzi M. Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis. Rheumatology (Oxford) 2009, 48(3):315-316.
170. Inanc N., Dalkilic E., Kamali S., Kasapoglu-Günal E., Elbir Y., Direskeneli H., et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007, 26(1):17-23.
171. Bogliolo L., Alpini C., Caporali R., Scirè C.A., Moratti R., Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005, 32(3):511-515.
172. Ouédraogo D.D., Palazzo E., Nicaise-Roland P., Somogyi N., Grootenboer-Mignot S., Hayem G., et al. Anti-cyclic citrullinated peptide antibodies (CCP2) in patients with psoriatic arthritis. Clin Exp Rheumatol 2007, 25(6):930-931.
173. Alenius G.M., Berglin E., Rantapää Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006, 65(3):398-400.
174. Vander Cruyssen B., Hoffman I.E., Zmierczak H., Van den Berghe M., Kruithof E., De Rycke L., et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005, 64(8):1145-1149.
175. Silvy F., Bertin D., Bardin N., Auger I., Guzian M.C., Mattei J.P., et al. Antinuclear antibodies in patients with psoriatic arthritis treated or not with biologics. PLoS One 2015, 10(7).
176. Hoffmann J.H., Hartmann M., Enk A.H., Hadaschik E.N. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011, 165(6):1355-1358.
177. Saraceno R., Specchio F., Torres T., Nisticò S.P., Rizza S., Chimenti S. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study. J Am Acad Dermatol 2012, 66(5):e180-e182.
178. Saraceno R., Chimenti M.S., Chimenti S. The significance of the development of antinuclear antibodies during infliximab treatment. J Am Acad Dermatol 2013, 69(2):314.
179. Hoxha A., Calligaro A., Tonello M., Ramonda R., Carletto A., Paolazzi G., et al. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study. Joint Bone Spine 2015, [pii: S1297-319X(15)00253-5].
180. Dolcino M., Lunardi C., Ottria A., Tinazzi E., Patuzzo G., et al. Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis. PLoS One 2014, 9.
181. Dolcino M., Ottria A., Barbieri A., Patuzzo G., Tinazzi E., Argentino G., et al. Gene Expression Profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One 2015, 10(6).
182. Sokolowska M., Niedzielska E., IciekM Bilska A., Lorenc-Koci E., Wlodek L. The effect of the uremic toxin cyanate (CNO-) on anaerobic cysteine metabolism and oxidative processes in the rat liver: a protective effect of lipoate. Toxicol Mech Methods 2011, 21:473-478.
183. Dalmády S., Kiss M., Képíró L., Kovács L., Sonkodi G., Kemény L., et al. Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris. Clin Dev Immunol 2013, 2013:474028.
184. Hoffman I.E., Demetter P., Peeters M., De Vos M., Mielants H., Veys E.M., et al. Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003, 62(5):455-459.
185. Aydin S.Z., Atagunduz P., Temel M., Bicakcigil M., Tasan D., Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 2008, 47(2):142-144.
186. Rodrigues I.K., Andrigueti M., de Oliveira Gil I.D., de Lucca Schiavon L., de Andrade K.R., Pereira I.A., et al. An investigation into the relationship between anti-Helicobacter pylori and anti-Saccharomyces cerevisiae antibodies in patients with axial spondyloarthritis and Crohn disease. Rheumatol Int 2015, 35(2):359-366.
187. Wallis D., Asaduzzaman A., Weisman M., Haroon N., Anton A., McGovern D., et al. Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study. Arthritis Res Ther 2013, 15(5):R166.
188. Riente L., Chimenti D., Pratesi F., Delle Sedie A., Tommasi S., Tommasi C., et al. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol 2004, 31(5):920-924.
189. Teichmann J., Voglau M.J., Lange U. Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis. Rheumatol Int 2010, 30(12):1559-1563.